Results 51 to 60 of about 19,199 (220)

Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III

Современная ревматология
The article discusses the results of a comparative phase III clinical trial of the efficacy and safety of the biosimilar Complarate (CPR; JSC Generium, Russia) and the reference drug Actemra (ACT; F.
E. V. Akatova, Yu. S. Bakhareva, O. V. Bugrova, I. B. Vinogradova, E. V. Gerasimova, Yu. E. Drevina, O. B. Ershova, E. V. Zonova, Yu. I. Ivanova, E. P. Ilivanova, M. M. Kostik, D. G. Krechikova, D. A. Kusevich, A. L. Maslyansky, A. D. Meshkov, N. S. Mosesova, K. A. Nagornova, D. V. Nosovich, S. A. Polyakova, T. A. Popova, E. A. Smolyarchuk, V. N. Sorotskaya, Yu. G. Shvarts, L. N. Shilova, M. S. Shostak, I. Yu. Yunonin, N. E. Akhtyamova-Givirovskaya, R. A. Khamitov, O. A. Markova, E. I. Zagoruiko, E. V. Zuev   +30 more
doaj   +1 more source

Lower Urinary Tract Symptoms Among Females with Rheumatoid Arthritis: A Prospective Cross-Sectional Study

International Journal of General Medicine, 2021
Faris Abushamma,1,2 Narjis Nassar,1 Sulafa Omar Najjar,1 Sobhe Mahmoud Hijaze,1 Amer Koni,3,4 Sa’ed H Zyoud,4– 6 Amir Aghbar,1,2 Rifat Hanbali,7 Hashim Hashim8 1Department of Medicine, College of Medicine and Health Sciences, An-Najah National University,
Abushamma F, Nassar N, Najjar SO, Hijaze SM, Koni A, Zyoud SH, Aghbar A, Hanbali R, Hashim H   +8 more
doaj  

SERUM FETUIN-A LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Научно-практическая ревматология, 2019
Rheumatoid arthritis (RA) is the second most common rheumatic disease. In recent decades, there has been an active search for and study of biologically active substances involved in the pathogenesis of RA, which can serve as a starting point in designing
E. V. Papichev, B. V. Zavodovsky, L. E. Sivordova, Yu. R. Akhverdyan, Yu. V. Polyakova   +4 more
doaj   +1 more source

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) are overlapping yet distinct conditions within the SpA spectrum. As divergent immunophenotypes may influence disease course and therapeutic response, we compared immune cell subsets, cytokine profiles, and inflammatory mediators.
Natalie Frede, Nils Craig‐Müller, Silke Kohrt, Marei‐Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff   +11 more
wiley   +1 more source

Diagnostic Values of DAS28 and DAS28-squeeze in Evaluating Rheumatoid Arthritis Disease [PDF]

, 2016
Background : In recent years, rheumatoid arthritis (RA) uses a “treat to target” treatment strategy. This strategy requires a valid and accurate tool for assessing disease activity.
Santosa, D. (David), Hidayat, R. (Rudy), Prasetyo, M. (Marcel), Nugroho, P. (Pringgodigdo)   +3 more
core  

The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 [PDF]

Arthritis Research & Therapy, 2006
AbstractThe objective of this work was to assess the convergent validity of a previously developed rheumatoid arthritis medical records-based index of severity (RARBIS) by comparing it with the 28-joint Disease Activity Score (DAS28). This study was conducted in subjects within the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study ...
Sato, Masayo, Schneeweiss, Sebastian, Scranton, Richard, Katz, Jeffrey, Weinblatt, Michael, Avorn, Jerome, Ting, Gladys, Shadick, Nancy, Solomon, Daniel   +8 more
openaire   +4 more sources

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)

Indonesian Journal of Rheumatology, 2018
Background Aim of this research is to assess the efficacy and safety of tocilizumab (TCZ) in combination with methotrexate (MTX) in Indonesian patients with moderate to severe active rheumatoid arthritis (RA) who have an inadequate response to non ...
Bambang Setyohadi, Harry Isbagio, Rachmat Gunadi Wachjudi, Joewono Soeroso, Handono Kalim, Deddy Nur Wachid Achadiono   +5 more
doaj   +1 more source

Disease activity correlates and functionality in patients with rheumatoid arthritis – real-world experience from a South Asian country

Rheumatology, 2022
Introduction There is a lack of data assessing disease activity in patients with rheumatoid arthritis from Pakistan. We sought to determine the correlation between Disease Activity Score 28 (DAS28) and disease activity parameters and the modified Health ...
Noreen Nasir, Hafsa Majid, Ayesha Habib Khan, Safia Awan, Mohammed Mehmood Riaz   +4 more
doaj   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source